Diet and exercise can help some type-2 diabetes patients save around $500 in medical expenses every year.
J&J subsidiary Janssen has abandoned its patent lawsuit over the anti-seizure medication topiramate, which is part of Vivus's prescription weight-loss drug Qsymia.
An experimental Gelesis weight-loss drug seeks the middle ground between surgery and appetite suppressants.
Lawmakers criticized Columbia University chairman and professor of surgery Dr. Mehmet Oz for calling weight-loss supplements miracles on his TV program, despite lacking scientific proof to support those claims.
The bad-ad watchdog says the promotional website for the weight-loss medication Suprenza leaves out too much information.
The regulator wants more time to discuss post-marketing requirements.
A study shows that total knee replacement is rising—and occurring in more youthful people. The uptick tracks with the rise in obesity.
Gelesis is pouring money into its obesity "smart pill," and Novo reports weighty success among subjects taking liraglutide.
Eisai announced it was adding sales reps to promote its drug Belviq, while Vivus, maker of Qsymia, fights off a generic marketing application by Actavis.
Arena and Eisai are testing Belviq with appetite suppressant phentermine.
A national survey indicates that obesity rates for children ages 2 to 5 has fallen since the early 2000s, yet overall numbers remain largely unchanged and high.
Analyst Thomas Wei reviews the prescription slimming category and sees two different realities for Vivus and Arena.
The drugmaker's new subsidiary will provide behavior and activity training, among other services.
The company expects to join the prescription weight-loss market by 2014's third quarter.
The drugmaker says interim trial data meets FDA review requirements and is hoping for June 2014 approval.
The drugmaker says 20 jobs, or 17% of its workforce, will be gone by the end of the year.
Researchers think a two-hormone approach could help control diabetes and obesity.
The marketing push follows the September launch of a patient support program and the announcement it was doubling its sales force.
Eisai, the marketing half of the Arena-Eisai collaboration, plans to double the sales force by December.
A Credit Suisse analyst notes that the company will need to make a significant impact to meet even lowered expectations. A possible fix: more sales reps behind Belviq.
J&J grad Seth Fischer is replacing Zook as Vivus CEO, just two months after the former AstraZeneca exec's appointment.
The Centers for Disease Control and Prevention profiles the typical sleep aid user, and finds that eight hours does not mean consumers are sleeping without help.
Australia's price watchdogs are assessing the value of BMS cancer drug Yervoy; why a Phase II weight drug from Zafgen could open up the category; GSK halts a Crohn's trial; and Shire extends Santaris rare-disease collaboration
Eisai uses a lawsuit to prompt the DEA, AHRQ gets a new director, mWellness runs into adherence issues.
Eisai lobbies to push back Belviq's patent clock; a case against Paula Deen is dismissed; Merck and Avanir team up to promote Januvia; and another healthcare-reform measure is pushed back
GSK says change is afoot in China; Vivus fight reportedly results in a new CEO; Biogen Idec enters a collaboration in Edinburgh; Astellas wins and FDA approval; Myriad's patent fight continues
Drug makers say the AMA's labeling of obesity as a disease will prompt patient-physician conversations, but they have no plans to overhaul brands' messaging.
Novo Nordisk stresses that the company has not parted ways with Paula Deen, even as her other endorsement and business deals shrivel up.
Alexion plans on moving into new HQ in 2015, AMA declares obesity is a disease, FDA looks into Zyprexa patient deaths
Studies undercut Medtronic spine treatment benefit, AMA wars over obesity classification, Komen gets a new CEO, GSK offloads thrombosis meds, Lilly gains diabetes treatment, AZN chooses new site